Immunogenicity and safety of an intradermal chadox1 ncov-19 boost in a healthy population

HIGHLIGHTS

• who: Nawamin Pinpathomrat from the During the pandemic of COVID-19, caused by SARS-CoV-2, there were more than , million infected patients and more than , million deaths worldwide have published the Article: Immunogenicity and safety of an intradermal ChAdOx1 nCoV-19 boost in a healthy population, in the Journal: (JOURNAL)
• what: The aim of this current study was to focus on boosting immunity in Published in partnership with the Sealy Institute for Vaccine Sciences 2 addition to the conventional regimen of the existing vaccine; an inactivated SARS-CoV-2 vaccine (CoronaVac). Unfavourable local reactions . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.